For example, AFM-24, a BiTKe engaged IgG1-scFv fusion antibody of CD16 with epidermal growth factor receptor (EGFR) activating NK cells through CD16 receptor for targeting EGFR, is now in clinical Phase II for treating patients with lung, colorectal cancer, and metastasis [240]. This evidence concerns the gene EGFR and colorectal cancer.